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Introduction 
In 2010, the American Cancer Society reports that 
11% of cancer fatalities in men are due to prostate 
cancer, which makes it the second leading cause of 
cancer mortality (1). Prostate cancer can take an 
indolent or an aggressive course with metastatic 
potential. Common metastatic sites include lymph 
nodes, skeletal system, lungs and liver.  Here we 
describe an unusual case of prostate cancer 
metastasizing to the kidneys 16 years after the 
initial curative treatment with radical prostatectomy. 
Case Presentation  
A 74 year old Caucasian gentleman with history of 
prostate cancer status post radical prostatectomy 16 
years ago presented with increasing abdominal pain.  
Approximately 10 years following his prostatectomy, 
he was noted to have a rising PSA to 200ng/ml; 
therefore, androgen deprivation therapy (ADT) was 
initiated with leuprolide.  His disease remained stable 
while he was on ADT for approximately three years 
until he developed worsening abdominal pain with 
alternating constipation and diarrhea, decline in his 
performance status, and an unintentional weight loss 
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Abstract  
Introduction: Prostatic carcinoma has variable course of disease progression.  Patients with metastasis from prostate cancer can 
present with varying symptoms. 
Presentation of case: We report a rare case of prostate cancer with renal metastasis 16yrs following radical prostatectomy.  
Patient presented with rising PSA levels ten years after his prostatectomy. Although his disease stabilized for a three year period 
on androgen deprivation therapy, he ultimately died from progression of his renal metastasis. 
Conclusions: While prostate cancer can take an indolent course, some patients can have metastatic disease even years after the 
initial “curative” treatment.  Thus long-term follow-up is crucial in patients with prostate cancer, even many years following 
initial curative treatment.   
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of 30 pounds over a 2-month period. Metastatic 
workup with imaging demonstrated extensive 
mesenteric adenopathy, a large abdominal mass 
intimately involved with the left kidney (Figure 1), 
and a mass in the trigone of the bladder.  Bone scan 
was negative for metastatic lesions.  Biopsy of the 
left renal mass and the bladder mass were positive for 
prostatic adenocarcinoma, Gleason score 5+5, 
consistent with androgen-refractory metastatic prostate 
cancer (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 CT image of abdominal mass intimately involving the left kidney (arrow and circle demonstrate the infiltrative 
appearance of the left kidney, consistent with neoplasm) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Biopsy of renal mass (hematoxylin-eosin stain). Immunostains were positive for PSA, PSAP, and PSMA, consistent 
with metastatic prostatic adenocarcinoma. 
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Imaging further demonstrated the large left renal 
mass compressing on bilateral ureters causing severe 
bilateral hydronephrosis with creatinine remaining at 
baseline. Bilateral stents were placed to relieve the 
hydronephrosis.  Palliative radiation to the pelvis was 
administered followed by chemotherapy with Taxotere.  
Despite 5 cycles of Taxotere, patient’s PSA continued 
to rise to 1300ng/mL.  Repeat CT imaging revealed 
the mass involving the left kidney had significantly 
enlarged, with persistent 2 spiculated right upper lung 
lobe nodules and extensive abdominal 
lymphadenopathy.  The patient was subsequently 
started on a tyrosine kinase inhibitor in an attempt to 
downsize his renal mass, with plans for a possible 
radical nephrectomy with retroperitoneal lymph node 
dissection. However, the patient passed away from 
progression of his androgen-refractory metastatic 
prostate cancer shortly following initiation of his 
chemotherapy treatment. 
Discussion 
This case captures the unpredictable nature of the 
progression of prostate cancer. The patient underwent 
curative radical prostatectomy and had no evidence of 
biochemical recurrence for over 10years.  Once 
biochemical recurrence was noted, the disease was 
stabilized for 3 years on androgen deprivation therapy. 
However, this patient’s prostate cancer progressed to 
an androgen-refractory state and continued to progress 
despite radiation and chemotherapy. The patient 
subsequently passed away from wide spread 
metastasis of his disease, 16yrs after its primary 
presentation. 
Prostatic carcinoma has widely variable course of 
disease progression. While prostatectomy are 
performed with curative intent, some patients will 
experience metastasis despite treatment, even many 
years after initial surgery; thus long-term follow-up of 
these patients are crucial.  Common metastatic sites 
include regional and distant lymph nodes, bones, liver, 
and adrenal glands. Other sites of metastasis include 
lungs, brain, and in some rare instances, the 
gastrointestinal system (2).  
To our knowledge, there has only been six 
published case reports of prostate cancer metastasizing 
to the kidney (3-7, Table 1).  Patients with renal 
metastasis from prostate cancer can present with 
varying symptoms.  In one of the very first cases 
published that involved renal metastasis, the patient 
presented with acute renal failure secondary to 
metastasis of prostate cancer to the kidneys (3). 
Gunulosy et al reported a case where the patient with 
prostate cancer treated 5 years prior with total 
androgen blockage (orchiectomy and ciproterone 
acetate) presented with left ﬂank pain, hematuria and 
vomiting for one month (6).  Ibinaive et al presented 
an interesting case of a patient presenting with an 
infected renal cyst as a result of metastatic prostatic 
adenocarcinoma with widespread bony metastases (8). 
 
Table 1Published case reports of metastatic prostate adenocarcinoma to kidney 
Article 
   
 
Presentation 
Galindo et al (1996) 
 
 
acute renal failure 
Inatomi et al (1996) 
 
 
renal mass 
Denti el al (1999) 
 
 
renal mass 
Gunlusoy el al (2004) 
 
 
hematuria and flank pain 
Sakata et al (2011) 
 
 
renal mass 
Ibinaive et al (2012) 
 
 
infected renal cyst 
 
While prostate cancer can take an indolent course, 
some patients will have metastatic disease even years 
after the initial “curative” treatment, as illustrated in 
this case report where metastatic disease was fatal 
16years after radical prostatectomy. Krauss et al 
reported a case where the patient presented with 
metastatic disease 23years after his prostatectomy (9).  
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Conclusion 
Patients with prostate cancer must continue to have 
long-term follow-up, even many years following 
initial curative treatment. A full workup is warranted 
when metastatic disease is suspected, as prostate 
cancer can metastasize to rare sites such as the kidneys 
as demonstrated in this case. 
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